Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleSingle dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability
Author(s)de Vries M, van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, van Goor H(; Pain and Nociception Neuroscience Research Group
Journal, Volume, IssueBr J Clin Pharmacol. 2015 Oct 27. doi: 10.1111/bcp.12811. [Epub ahead of print]
Major outcome(s)No effect of a single low dose of THC on abdominal pain resulting from chronic pancreatitis in clinical study.
IndicationPainAbstract
MedicationDelta-9-THC

AIM: We aimed to assess the analgesic efficacy, pharmacokinetics, tolerability and safety of a single dose Δ9-THC in patients with chronic abdominal pain resulting from chronic pancreatitis (CP). METHODS: This was a randomized, single-dose, double-blinded, placebo-controlled, two-way cross-over study in patients suffering from abdominal pain as result of CP (n = 24), post hoc subdivided into opioid and non-opioid users. Δ9-THC (8 mg) or active placebo (5 mg / 10 mg diazepam) was administered orally in a double dummy design. RESULTS: No treatment effect was shown for delta VAS pain scores after Δ9-THC compared with diazepam. Δ9-THC was well absorbed with a mean tmax of 123 min. No significant differences were found between Δ9-THC versus diazepam for alertness, mood, calmness or balance. Feeling anxious and heart rate were significantly increased after Δ9-THC compared with diazepam. Most frequently reported adverse events (AEs) after Δ9-THC administration were somnolence, dry mouth, dizziness and euphoric mood. CONCLUSIONS: A single dose Δ9-THC was not efficacious in reducing chronic pain resulting from CP, but was well tolerated with only mild or moderate AEs. The PK results in CP patients showed delayed absorption and an increased variability compared to healthy volunteers.

Route(s)Oral
Dose(s)8mg
Duration (days)
Participants24
DesignControlled study
Type of publicationMedical journal
Address of author(s)Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
Full texthttp://www.ncbi.nlm.nih.gov/pubmed/?term=26505163

[Back to Overview]  [IACM Homepage]


up